Introduction {#S1}
============

The lower urinary tract (LUT, consisting of the bladder and bladder outlet) serves two main roles: to store and empty urine. LUT dysfunction occurs when either storage or voiding are impaired, resulting in urinary incontinence or retention. LUT dysfunction is common in patients with neurological disease and the general population ([@B4]; [@B20]). In the case of neurological disease, LUT dysfunction occurs because the normal pathways responsible for communication between the LUT and the neural micturition centers become disrupted. While the mechanism of idiopathic LUT dysfunction is not as obvious, the nervous system is thought to be at least partially implicated in the majority of cases. LUT dysfunction has profound effects which range from endangering patients' health \[as the case of poorly managed LUT dysfunction after spinal cord injury (SCI)\] to significantly impacting patients' quality of life \[as in the case of idiopathic over active bladder (iOAB) and post-stroke LUT dysfunction\].

While it is often assumed that paralyzed individuals prioritize recovery of ambulation, multiple studies have demonstrated that restoration of bladder function is ranked among the top 2--3 priorities, above goals such as regaining lower extremity function ([@B1]). Likewise, urinary incontinence after stroke is a well-known risk factor for long-term disability, depression and institutionalization ([@B21]). Current therapy for LUT focuses on managing these complications without addressing the underlying cause or attempting to normalize or restore function ([@B26]). Urinary incontinence, frequency and urgency present across diseases such as SCI, stroke, multiple sclerosis (MS) and iOAB. While the reasons for this may vary, detrusor overactivity (or uninhibited detrusor contractions) is a common physiologic phenomenon observed in these conditions. Multiple therapies exist for correcting urinary storage function; however, they are not always suitable populations (e.g., anticholinergic medications in patients with cognitive impairment; intravesical botulinum toxin in patients at risk for retention) and they do not attempt to restore normal LUT function. On the other hand, the premise of neuromodulation is to correct the underlying neurological deficit and thus restore function to an end organ. Some neuromodulation techniques are well-established in iOAB including sacral nerve stimulation ([@B3]) and percutaneous tibial nerve stimulation ([@B22]). We have recently developed a novel neuromodulation approach, Transcutaneous Electrical Spinal Cord Neuromodulation (TESCoN) a novel non-invasive neuromodulation technique to facilitate functional restoration after neurological injury ([@B8]). This modality engages the automaticity and the feedforward ([@B11]) features of the spinal neural networks to activate the intrinsic control of the spinal networks that is sufficient to enable recovery of voluntary control. We have previously demonstrated that acute TESCoN facilitates urinary storage and promotes bladder emptying in individuals with SCI during urodynamic studies ([@B9]). Patients experienced decreased detrusor overactivity, exhibited increased bladder capacity and improved detrusor-sphincter dyssynergia when stimulation was delivered at a high frequency; on the other hand, when stimulation was delivered at a low frequency subjects demonstrated improved voiding efficiency. These changes in LUT function were only noted during active stimulation. In this study we wished to determine whether repetitive stimulation over the course of several weeks can retrain the spinal neural networks to relearn timely storage and voiding. In addition, given the similarities in storage LUT symptoms and physiologic phenomena (e.g., detrusor overactivity) across multiple conditions, we wished to expand the application of TESCoN to LUT dysfunction due to stroke, MS and iOAB. Finally, our objective was to provide a clinical assessment of the effect of TESCoN on the LUT by examining changes in voiding diaries and validated clinical questionnaire following a course of the therapy.

Materials and Methods {#S2}
=====================

Patient Recruitment {#S2.SS1}
-------------------

This study was approved by the Institutional Review Board of Rancho Research Institute, the research arm of Rancho Los Amigos National Rehabilitation Center, Downey, CA, United States. All research participants signed an informed consent form before the start of the study and consented to their data being used in future publications and presentations. Five patients (four males and one female) with stable (greater than 1-year post diagnosis) SCI at T8 or above who used clean intermittent catheterization (CIC), five patients (three males and two females) with stable cortical stroke (greater than 1-year post diagnosis), three female patients with progressive MS symptoms for at least 1 year and one female patient with idiopathic OAB were recruited ([Table 1](#T1){ref-type="table"}). All patients experienced symptoms of urinary incontinence and sensate (i.e., non-SCI) patients reported urinary frequency and urgency.

###### 

Table summarizing 14 patients, their pathology (*n* = 5 SCI, 5 Stroke, *n* = 3 MS and *n* = 1iOAB) location of injury, severity of injury, months post injury, current bladder management technique, LUT symptoms and current medications.

  **Pt\#**   **Age (yrs)**   **Gender**   **Pathology**   **Location**          **Severity**   **Months post**   **Bladder management**   **Lower urinary tract symptoms**   **Lower urinary tract medications**
  ---------- --------------- ------------ --------------- --------------------- -------------- ----------------- ------------------------ ---------------------------------- ----------------------------------------
  P1         25--35          M            SCI             T4                    AIS A          18 m              CIC                      Incontinence                       None
  P2         25--35          F            SCI             T6                    AIS A          29 m              CIC                      Incontinence                       Mirabegron 50 mg
  P3         40--50          M            SCI             C4                    AIS C          20 m              CIC                      Urge Incontinence                  None
  P4         35--45          M            SCI             T5                    AIS A          135 m             CIC                      Urge Incontinence                  Tolterodine LA 4 mg
  P5         50--60          M            SCI             T9                    AIS C          48 m              CIC                      Urgency/Incontinence               Solifenacin 10 mg
  P6         40--50          M            CVA             L Basal Ganglia                      50 m              Volitional               Urgency/Nocturia                   Tolterodine LA 4 mg
  P7         40--50          M            CVA             R Basal Ganglia                      36 m              Volitional               Urgency/urge incontinence          Tolterodine LA 4 mg
  P8         55--65          F            CVA             L Centrum Semiovale                  78 m              Volitional               Urge incontinence                  Tolterodine LA 4 mg
  P9         55--65          F            CVA             L Basal Ganglia                      75 m              Volitional               Urge incontinence                  Oxybutynin 5 mgTID
  P10        55--65          M            CVA             LMCA                                 75 m              Volitional               Urgency/Frequency                  None
  P11        20--30          F            MS                                                   48 m              Volitional               Urge incontinence                  None
  P12        55--65          F            MS                                                   240 m             Volitional               Incontinence                       None
  P13        35--45          F            MS                                                   24 m              Volitional               Urge incontinence                  Tolterodine LA 4 mg, Tamsulosin 0.8 mg
  P14        55--65          F            iOAB                                                 48 m              Volitional               Urge Incontinence/Frequency        None

SCI, spinal cord injury; CVA, cerebral vascular accident; MS, multiple sclerosis; CIC, clean intermittent catheterization.

Initial Assessment {#S2.SS2}
------------------

Each patient underwent a detailed medical history and physical examination and completed an assessment of LUT symptoms using the Neurogenic Bladder Symptom Score (NBSS). A baseline urodynamic study was performed in SCI and stroke subjects according to International Continence Society (ICS) guidelines using a Goby Urodynamics System from Laborie (Ontario, Canada). In order to mimic a clinical setting where patients may not be evaluated with urodynamics prior to therapy, MS and idiopathic OAB subjects were assessed only with a detailed history and physical, a voiding diary, and the NBSS. Following the initial visit, each subject completed a 4-day voiding diary.

Delivery of Spinal Stimulation {#S2.SS3}
------------------------------

Stimulation was delivered using a proprietary TESCoN device (spineX, Inc.) ([@B8]). The stimulation waveform consisted of two alternating pulses of opposite polarities separated by a 1 μS delay to form a delayed biphasic waveform. The pulses consisted of a high frequency biphasic carrier pulse (10 KHz) combined with a low frequency (30 Hz) burst pulse each with a pulse width of 1 ms. Stimulation was applied using an adhesive electrode over the interspinous ligaments of T11 and L1 serving as the cathode and two adhesive electrodes over the iliac crests as the anodes. The frequencies were selected based on our previous findings demonstrating greatest reduction in incontinence and increase in bladder capacity ([@B9]).

Identification of Stimulation Parameters {#S2.SS4}
----------------------------------------

Patients with SCI and stroke underwent formal evaluation for selection of stimulation parameters as previously published ([@B9]). In brief, a urodynamic two-port urethral catheter and a urodynamic rectal catheter were placed to measure intravesical (P~ves~), external urethral sphincter (P~ura~) and abdominal (P~abd~) pressures, respectively. Stimulation was delivered as described above. Dose response curves were constructed for each parameter with incremental increase in stimulation intensity. The stimulation intensity that generated a noticeable change in P~ura~ with little to no change in P~det~ was selected ([Figure 1](#F1){ref-type="fig"}). This stimulation intensity did not cause any discomfort to the patients. Urodynamic studies were then performed according to ICS guidelines with concurrent TESCoN stimulation. Again, to mimic a clinical setting which precludes such an assessment, subjects with MS and idiopathic OAB were stimulated at a preselected frequency (30 Hz) and location (T11 and L1). Stimulation intensity was set as the highest current that did not cause cutaneous discomfort or cause any muscle activation in pelvic floor muscles or lower extremity muscles.

![Changes in detrusor and urethral pressures with changing parameters of TESCoN. Representative patient demonstrating the protocol to identify parameters of TESCoN that generates minimal change in Pdet along with a change in Pura. In this case stimulation at L1 at 100 mA (yellow box) generated no change in Pdet while Pura increased from ∼25 to 32 cm of H20 (green arrows) between TESCoN On and TESCoN off. Note the increase in both the Pura and Pdet at L1 120 mA.](fnsys-14-00001-g001){#F1}

TESCoN Therapy Course {#S2.SS5}
---------------------

Following the baseline evaluation, the patients were invited to return for an 8-week long course of TESCoN Subjects received stimulation for 90 min. Each subject completed three stimulation sessions a week.

Post-stimulation Assessment {#S2.SS6}
---------------------------

Within 1 week after the last stimulation session, SCI and stroke patients completed another clinical urodynamic study in the absence of TESCoN. All patients also completed the NBSS at this time and submitted a voiding diary starting 4 days prior to the final assessment.

Data and Statistical Analysis {#S2.SS7}
-----------------------------

The following urodynamic variables were collected in SCI and stroke subjects: (1) Bladder capacity, (2) Voiding efficiency, (3) Maximum detrusor pressure during voiding contraction, (4) Change in urethral sphincter pressure during filling and voiding contraction, (5) volume at first sensation and (6) time between bladder capacity and beginning of voiding contraction. "ΔP~ura~ Filling" was defined as the change in pressure observed in P~ura~ during the filling cycle. "P~ura~ Baseline" was defined as the pressure in the P~ura~ prior to start of filling. "ΔP~det~ void" and "ΔP~ura~ void" were defined as the change in pressures observed in P~det~ and ΔP~ura~, respectively, between bladder capacity and voiding. The paired *t*-test was used to determine the significance of differences in urodynamic parameters, NBSS scores of participants and number of daily voids and incontinence episodes with and without TESCoN and before and after therapy.

Results {#S3}
=======

Urodynamic Assessment of SCI and Stroke Patients {#S3.SS1}
------------------------------------------------

During baseline urodynamics, SCI patients demonstrated detrusor overactivity at low volumes, low voiding efficiency and detrusor sphincter dyssynergia during voiding. Stroke patients demonstrated low bladder capacity, detrusor overactivity, and appropriate voiding efficiency ([Figure 2](#F2){ref-type="fig"}; [@B28]; [@B29]). Acute delivery of TESCoN in SCI patients reduced detrusor overactivity, increased bladder capacity, improved coordination between detrusor and the external urethral sphincter and increased voiding efficiency ([Figure 3](#F3){ref-type="fig"}), consistent with our earlier observations ([@B9]). In contrast, stroke patients did not demonstrate a change in bladder capacity or voiding efficiency. However, stroke patients exhibited an increase in the volume at first bladder sensation, and a significant increase in the ability to delay urination, as measured by the time between reaching bladder capacity and initiation of voiding *(P* \< *0.05)* ([Figure 4](#F4){ref-type="fig"}). After completing the 8-week therapeutic intervention, both sets of patients (*n* = 5 Stroke and *n* = 5 SCI) demonstrated an increased bladder capacity (*P* \< *0.05*, [Figures 5A,F](#F5){ref-type="fig"}) (without TESCoN); however, no change in voiding efficiency was observed in either group ([Figures 5B,G](#F5){ref-type="fig"}). The average baseline pressure recorded at the urethral port (P~ura~) and the change in P~ura~ during the filling phase of the urodynamic cycle were higher (*P* \< *0.05*) after compared to before therapy ([Figures 5C,D,H,I](#F5){ref-type="fig"}). Detrusor pressure (P~det~) during voiding did not change before vs. after therapy ([Figures 5E,J](#F5){ref-type="fig"}).

![Changes in urodynamic studies without and with TESCoN. Representative urodynamic study for a stroke patient, **(A)** before therapy (PreTherapy) without and **(B)** with TESCoN and **(C)** after therapy (PostTherapy) and spinal cord injured (SCI) **(D)** before therapy (PreTherapy) without and **(E)** with TESCoN and **(F)** after therapy (PostTherapy). Note the increased bladder capacity (time prior to detrusor contraction), improved flow, improved detrusor and sphincter coordination and increase in urethral pressure during filling both with TESCoN at PreTherapy and PostTherapy (without TESCoN). Black arrow marks the occurrence of detrusor overactivity.](fnsys-14-00001-g002){#F2}

![Changes in urodynamic parameters during acute stimulation in SCI subjects. Mean ±SE (*n* = 5 SCI) without (white bar) and with (red bar) acute delivery of TESCoN. **(A)** bladder capacity, **(B)** Voiding efficiency, **(C)** changes in pressure during filling vs. voiding to demonstrate the improvement in Detrusor-Sphincter Dyssynergia (DSD) without (black) and with TESCoN (red). \* statistically significant from without TESCoN at *P* \< *0.05.*](fnsys-14-00001-g003){#F3}

![Changes in urodynamic parameters during acute stimulation in stroke subjects. Mean ±SE (*n* = 5 Stroke) **(A)** bladder capacity, **(B)** Voiding efficiency, **(C)** volume at first sensation during urodynamic study without (white bar) and with (red bar) acute TESCoN and **(D)** time window between bladder capacity and voiding in stroke patients. \* statistically significant from without TESCoN at *P* \< *0.05.*](fnsys-14-00001-g004){#F4}

![Changes in urodynamic parameters after a 8-week course of stimulation. mean ±SE (*n* = 5 SCI patients) **(A)** bladder capacity, **(B)** Voiding efficiency **(C)** baseline Pura prior to filling, **(D)** ΔP~ura~ during bladder filling, **(E)** ΔP~det~ during voiding as observed during clinical urodynamic studies at Pre-Therapy and Post-Therapy without TESCoN. mean ±SE (*n* = 5 stroke patients) **(F)** bladder capacity, **(G)** Voiding efficiency **(H)** baseline Pura prior to filling, **(I)** ΔP~ura~ during bladder filling, **(J)** ΔP~det~ during voiding as observed during clinical urodynamic studies at Pre-Therapy and Post-Therapy without TESCoN. ^∗^Significantly different from Pre-Therapy at *P* \< *0.05.*](fnsys-14-00001-g005){#F5}

Clinical Assessment of Patients {#S3.SS2}
-------------------------------

All patients underwent a clinical assessment in the form of a 4-day voiding diary and NBSS. Eleven (*n* = 4 SCI, *n* = 5 Stroke and *n* = 2 MS) out of thirteen neurogenic patients reported at least a five-point decrease (minimal clinically important difference, MCID) in the NBSS ([@B30]; [Figure 6A](#F6){ref-type="fig"}). The mean score in the NBSS decreased from 35.9 ± 2.6 to 26.6 ± 3.1 *(P* \< *0.05)* with the highest change being 34 points and the lowest being 0 ([Figures 6C,D](#F6){ref-type="fig"}). Note that significant decrease in NBSS scores were observed in all pathologies ([Figure 6E](#F6){ref-type="fig"}). The distribution of NBSS decrease among the different underlying pathologies showed no obvious trends. All patients also reported a significant decrease in the number of incontinence episodes/day (∼68% reduction in leaks, *P* \< *0.05*) ([Figure 7A](#F7){ref-type="fig"}), a reduction (12%) in the number of voiding/CIC episodes per day ([Figure 7B](#F7){ref-type="fig"}) and a significant reduction (∼37%) in night time voiding/CIC episodes as recorded on the voiding diary ([Figure 7C](#F7){ref-type="fig"}). No Adverse Events (AE) were reported. All patients reported to be satisfied with the therapy and would have continued beyond the 8 weeks if the therapy was offered.

![Changes in NBSS parameters after TESCoN therapy **(A)** Neurogenic Bladder Symptom Score (NBSS) at Pre-Therapy and Post-Therapy for the 14 patients tested. **(B)** Mean ± SE (*n* = 14 patients) NBSS scores at Pre-Therapy and Post-Therapy. **(C)** Distribution of NBSS score decrease across the 14 patients tested, note only 5 SCI patients are plotted since 5th patient observed a change of 0, **(D)** decrease in NBSS scores relative to the initial NBSS scores, **(E)** mean ±SE (*n* = 5 SCI patients, *n* = 5 stroke and *n* = 3 MS) NBSS scores at Pre-Therapy and Post-Therapy. MCID, minimal clinically important difference. ^∗^statistically significant from Pre-therapy at *P* \< *0.05.*](fnsys-14-00001-g006){#F6}

![Changes in voiding diary parameters after TESCoN therapy. **(A)** Number of urinary incontinence at Pre-Therapy and Post-Therapy for the 14 patients tested, mean ± SE percent decrease in incontinence episodes for the 4 patient groups and all patients (*n* = 14 patients) tested, **(B)** mean ± SE percent decrease in number of voids for the 4 patient groups and all patients (*n* = 14 patients) tested and **(C)** mean ±SE percent decrease in number of night time voiding/CIC episodes during the night (10pm to 6am) for the 4 patient groups and all patients (*n* = 14 patients) tested. ^∗^Significanatly different from pretherapy at *P* \< 0.05.](fnsys-14-00001-g007){#F7}

Discussion {#S4}
==========

Neuromodulation Enables Restoration of Sensation and Motor Control of LUT {#S4.SS1}
-------------------------------------------------------------------------

Multiple components of the nervous system play a role in LUT control. Thus, when one or more components of the nervous system are affected by a disease, LUT dysfunction can ensue. Although modern management techniques have ensured that LUT dysfunction is rarely dangerous, it almost inevitably has a marked impact on patients' quality of life. Some current therapies for LUT dysfunction in neurogenic and idiopathic situations are effective for preventing incontinence (e.g., anticholinergics, beta-agonists, botulinum toxin injection) but they do not restore normal bladder sensation or voiding function and sometimes achieve continence at their expense. On the other hand, spinal neuromodulation is a technique whose premise is to restore neural control functions by delivering a sub-motor threshold electrical stimulus that can transform the controlling neural networks into more functional physiological states. After 8 weeks of non-invasive spinal cord stimulation, bladder capacity increased. SCI patients also demonstrated improved detrusor-sphincter dyssynergia during detrusor contractions. All patients reported an improved sensation of bladder fullness and an increased latency time between sensation of urgency and the first episode of detrusor overactivity (or volitional voiding contraction). These effects appeared to be durable as they were observed even 1 week after therapy was concluded.

A commons question in the field of neuromodulation is, how epidural and transcutaneous spinal stimulation compare? Some of the more Important comparisons are (1) the ability to deliver the desired stimulation parameters to the most functionally effective neuronal networks for a given target organ system, (2) patient acceptability and ease and accessibility of delivery of the intervention (3) cost of the intervention and (4) safety of the intervention. To date, there is insufficient knowledge to weigh the advantages, but it seems reasonably safe to conclude that both approaches should continue to be developed and tested. Given the data to date, it seems almost inevitable that the best choice of approach will be based on the net result of pros and cons for a given patient as judged by the patient, the physician and the caregivers.

To briefly expand on some of these points, it is obvious that using the transcutaneous approach, multiple organ systems can be targeted simply by moving the electrode along the length of the spinal cord ([@B9], [@B10]; [@B7]; [@B19]; [@B23]; [@B24]; [@B17]; [@B25]). Epidural stimulation has been effective in treating both autonomic ([@B15]; [@B16]; [@B18]) and motor functions ([@B14]; [@B2]; [@B13]; [@B27]) while maintaining the overall location of the implant even though the scope of the neural networks being neuromodulated may be more limited compared to transcutaneous stimulation. Evidence to date suggest that the transcutaneous approach in general has a greater advantage because of a more encompassing combination of networks that can be modulated to multiple organ systems. The activation of a broader network may enable multiple muscle groups and rely of the automaticity and feedforwardness of the spinal cord ([@B11]). A disadvantage of the transcutaneous approach is the inconvenience to frequently don and doff the electrodes and the lower spatial resolution compared to the epidural approach. While only a side-by-side comparison in the same patient may provide more definitive answers, the transcutaneous approach definitely can help screen potential responders and provide insights regarding effective sights for stimulation. One could proceed from the transcutaneous approach to the Implantation strategy if this would be viewed as a more long-term solution. The reverse approach, however, would be more problematic.

Clinically Significant Levels of LUT Function Can Be Restored {#S4.SS2}
-------------------------------------------------------------

As important as the physiological changes observed on urodynamic testing were the clinical improvements assessed by the voiding diary and the NBSS. The NBSS is a validated questionnaire ([@B30]) that addresses common urological complaints in patients with neurological disease (e.g., incontinence, frequency, urgency and their impact on quality of life). The ability of NBSS to detect a meaningful clinical change has been recently shown in a pilot study of SCI and multiple sclerosis patients, receiving botulinum toxin injections for neurogenic urinary incontinence ([@B5]). Over 85% of the neurogenic bladder patients in our study reported a statistically significant and clinically meaningful improvement in the overall NBSS score after TESCoN therapy was completed. Among the various domains of the questionnaire, there was improvement in the incidence of incontinence, quality of life and voiding/storage domains of the NBSS. As expected, there was no significant change in the consequences domain of the NBSS as the questions in this section of the questionnaire represent chronic problems related to the urinary tract (e.g., bladder and kidney stones), that would not be expected to improve immediately with positive change in LUT function. However, all patients also reported either a significant decrease in the number of urinary incontinence episodes per day or a decrease in the number of night time voiding cycles. Similar to the responses observed in the NBSS scores, no obvious trends were observed across the pathologies.

Mechanistic Factors That Contribute to Restoration of LUT Functions {#S4.SS3}
-------------------------------------------------------------------

Although the mechanistic details of how spinal neuromodulation can improve bladder function is not known, multiple but highly linked mechanisms probably contribute to the observed improvements. We postulate that stimulation modulates both afferent and efferent spinal networks into a more functional state. Neuromodulation may alter the responsiveness of spinal networks to bladder filling and emptying and increase the conscious awareness of these states. After chronic TESCoN therapy, subjects reported improved bladder sensation and decreased urinary urgency. Together, these findings suggest that parts of the CNS responsible for conscious sensation in the brain may have been re-engaged along with re-activation and/or retraining of local spinal centers controlling the LUT, reflecting a highly significant level of functional neural plasticity. It is interesting to note that despite the varied pathology, location and severity of injury, the spinal control of detrusor and urethral sphincter muscles were intact and could be transformed using a non-invasive modality. Our finding that voiding efficiency after 8 weeks of treatments did not change when urodynamic test was repeated in absence TESCoN suggests that the parasympathetic system, that drives bladder emptying, may require ongoing stimulation in order to induce a functional change. On the other hand, it appears that TESCoN can induce long standing neuroplasticity in the sympathetic and somatic system, which drives bladder storage, as evidenced by our finding that bladder capacity and P~ura~ showed improvement even in the absence of stimulation.

Despite the potential shortcomings of the limited number of patients and lack of sham stimulation which will be addressed in future randomized controlled clinical trials, these data demonstrate the ability to transform the neural control of bladder function from a dysfunctional to a functional state using non-invasive spinal neuromodulation. Our previous results have demonstrated improvement in multiple functions (locomotion and autonomic function) with spinal neuromodulation during function rehabilitation ([@B12]; [@B6]; [@B7]). In this study, however, since the patients were seated while receiving TESCoN therapy, minimal improvements in locomotor function were observed. TESCoN could prove to be a critical component of in our clinical toolbox while designing rehabilitation therapies for patients that suffer from multiple organ dysfunction (autonomic and motor) due to paralysis. In addition, future studies will also identify potential chronic changes in the cortex during simultaneous functional MRI recordings during urodynamic studies. These data allow us to speculate about multiple neural mechanisms that can account for end-organ dysfunction in neurogenic and non-neurogenic states (e.g., loss of connectivity between centers responsible for end organ control, formation of aberrant neural connections resulting in abnormal function). However, the intrinsic spinal networks controlling the LUT seem to not only persist post injury, but also have the potential to undergo transformation to a more functional state. These observations are consistent with our studies of non-invasive spinal cord stimulation in other applications such as lower extremity ([@B12]; [@B6]), and upper extremity functional rehabilitation ([@B7]; [@B19]), where we have consistently observed some restoration of voluntary control in individuals clinically diagnosed with complete motor and sensory paralysis. We hypothesize that neuromodulation enables activity-dependent mechanisms that transform functionally incompetent spinal and supraspinal networks to higher functional states. The idea that neuromodulation can affect a part of the CNS remote from the site of stimulation is supported by data from other groups. For example, sacral nerve stimulation (a peripheral nerve neuromodulation modality commonly employed for idiopathic overactive bladder) is known to generate changes in brain signaling even during acute delivery of stimulation ([@B3]). The encouraging findings that TESCoN can improve LUT symptoms in a variety of disease states encourages the exploration of its use in other brain pathologies associated with LUT dysfunction (e.g., Parkinson's disease, cerebral palsy), thus expanding the potential impact of this technology to a wider range of diseases.

Conclusion {#S5}
==========

We have successfully demonstrated that TESCoN can (1) reduce detrusor overactivity, increase bladder capacity and reduce episodes of incontinence in patients with SCI, stroke, multiple sclerosis and idiopathic over active bladder, (2) functional transformation of the sensory component of bladder control to improve sensation of fullness bladder and awareness by delaying the time between reaching bladder capacity and initiation of voiding, and (3) significantly reduce the number of incontinence episodes and night time voids that also reflects in the changes in NBSS scores. These observations suggest that the level of functional autonomy that is intrinsic to the neural circuitry that controls bladder function. This is a highly attractive clinical target for regaining greater levels of function in SCI and other etiologies of neurogenic bladder because it is a non-invasive form of neuromodulation that can re-engage and restore, via activity-dependent mechanisms, the automaticity intrinsic to the autonomic control of the LUT.
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